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ABSTRACT 
Background 
Dementia with Lewy bodies is characterized by transient clinical features, including 
fluctuating cognition and visual hallucinations, implicating dysfunction of cerebral hub 
regions, such as the pulvinar nuclei of the thalamus. However, the pulvinar is typically 
only mildly affected by Lewy body pathology in dementia with Lewy bodies, suggesting 
additional factors may account for its proposed dysfunction.  
Methods 
We conducted a comprehensive analysis of post-mortem pulvinar tissue using whole-
transcriptome RNA sequencing, protein expression analysis and histological 
evaluation.  
Results 
We identified 321 transcripts as significantly different between dementia with Lewy 
bodies cases and neurologically normal controls, with gene ontology pathway analysis 
suggesting enrichment of transcripts related to synapses and positive regulation of 
immune function. At the protein level, proteins related to synaptic efficiency were 
decreased, whilst general synaptic markers remained intact. Analysis of glial sub-
populations revealed astrogliosis without activated microglia, which was associated 
with synaptic changes but not neurodegenerative pathology.  
Discussion 
These results indicate that the pulvinar, a region with relatively low Lewy body 
pathological burden, manifests changes at the molecular level which differ from 
previous reports in a more severely affected region. We speculate that these 
alterations result from neurodegenerative changes in regions connected to the 
pulvinar, and likely contribute to a variety of cognitive changes resulting from 
decreased cortical synchrony in dementia with Lewy bodies. 
 
 
 
 
INTRODUCTION 
Dementia with Lewy bodies (DLB) is thought to be the second most common form of 
neurodegenerative dementia after Alzheimer’s disease (AD) (1). Clinically, DLB is 
marked by four core symptoms of fluctuating cognition, parkinsonism, visual 
hallucinations and rapid eye movement sleep behavior disorder, against the backdrop 
of global cognitive decline (2). Pathologically, DLB is characterized by pathological 
aggregates of α-synuclein in nerve cell bodies and nerve cells processes termed Lewy 
bodies and Lewy neurites, respectively (3). However, varying degrees of AD-type 
pathology, consisting of extracellular amyloid-β plaques and intraneuronal tangles of 
abnormally hyperphosphorylated tau, are frequent concomitant features (4, 5).  
Visuo-perceptual and attentional functions are impaired in DLB (6-8), and may 
promote the occurrence of visual hallucinations (9-12). The pulvinar contributes to 
visuo-perceptual and attentional functions (13), has reciprocal connectivity with 
widespread cortical regions (14), and is a putative ‘hub’ that coordinates neural activity 
across the cortex (15). Dysfunction of highly interconnected hubs has been postulated 
as important in eliciting the clinical manifestation of neurodegenerative disorders, 
including DLB, by diminishing network coherence and coordinated neural activity (16). 
Whilst most research on network connectivity in neurodegenerative disorders has 
focused on AD (17), connectivity is decreased to a greater degree in DLB compared 
to AD, with particular impairments in long-distance connections (18). 
Metabolic deficits (19) and increased tissue diffusivity (20) have previously been 
reported in the pulvinar in DLB. We have previously reported neuronal loss in the 
pulvinar, which may promote attentional dysfunction and visual hallucinations in DLB 
(21). However, Lewy body pathology is relatively mild in the pulvinar (22) and the sub-
regions most severely affected by α-synuclein aggregation did not show neuronal loss 
(21). Therefore, it is difficult to relate the myriad changes described previously in the 
pulvinar with the manifest burden of α-synuclein pathology. On that basis, we have 
investigated differential gene expression with whole-transcriptome RNA sequencing 
(RNA-seq), protein quantification assays and histological analysis to evaluate changes 
to the pulvinar which may be relevant to the clinical features of DLB.  
METHODS 
 
 
Tissue preparation 
All tissue was obtained from Newcastle Brain Tissue Resource (NBTR), a UK Human 
Tissue Authority-approved research tissue repository, and ethical approval was 
granted by Newcastle University Ethics Board and the Joint Ethics Committee of 
Newcastle and North Tyneside Health Authority (ref: 08/H0906/136). DLB cases had 
been part of prospective clinical studies, and had received detailed clinical 
assessments during life and case note review after death. All cases had consented to 
the use of their brain tissue for research purposes. Neuropathological assessment was 
conducted according to standardized neuropathological diagnostic procedures (4, 23-
26). Clinical and pathological data was collated to establish a clinico-pathological 
consensus diagnosis. The present study included cases with a clinical diagnosis of 
DLB confirmed by neuropathological post-mortem assessment. DLB cases were 
compared to aged individuals with an absence of neurological features intra vitam low 
age-associated neurodegenerative pathology. Demographic information is provided in 
Supplementary Tables 1 and 2.  
At autopsy, tissue from the left hemisphere was cut into 1 cm thick coronal sections 
and rapidly frozen at -80°C between copper blocks. The pulvinar was identified by its 
location in the posterior pole of the thalamus from which approximately 50 mg of tissue 
was dissected with a cooled scalpel (27).  Frozen tissue was obtained from a cohort 
of 15 control and 14 DLB cases (Supplementary Table 1).  
The right hemisphere was fixed in 10% formalin and dissected into blocks for 
neuropathological assessment. 10 μm sections were taken from the pulvinar at the 
level of the posterior aspect of the lateral geniculate nucleus and the amygdala and 
stained with antibodies against a range of protein targets using Menarini Menapath 
Polymer detection kits (Menarini, Berkshire, UK) and counterstained with 
haematoxylin. Fixed pulvinar tissue was obtained from a cohort of 14 controls and 14 
DLB cases (Supplementary Table 2). 
 
RNA isolation and sequencing 
Frozen tissue was placed in 5-10 volumes of pre-cooled RNAlater solution (Ambion, 
Warrington, UK) and stored at -80°C. Tissue was removed from RNAlater and rapidly 
 
 
homogenized in TRI-reagent (Ambion) and stored at -80°C. RNA was extracted using 
a spin column method, as per manufacturer’s instructions (Ribopure, Ambion), and 1 
μg of RNA was DNase-treated (Turbo-DNase free, Ambion). The RNA concentration 
was determined using a Nanodrop ND 1000 Spectrophotometer (Nanodrop 
Technologies) and RNA integrity number (RIN) examined with an Agilent 2100 
Bioanalyzer RNA 6000 Nano Assay (Agilent Technologies, Stockport, UK). 
RNA-seq libraries were prepared using TruSeq Ribo Zero Gold kits (Illumina, CA, 
USA). Clustering was performed with 10 nM libraries pooled in groups of six libraries 
per lane of each flow cell. We then sequenced 200 bp paired-end libraries on a 
HiSeq2500 sequencer. Sequence reads were aligned using Salmon []. Genes with low 
expression (row mean counts for <1) were removed, then differential expression was 
estimated using DESEQ2 (28) using the following model to correct for biological 
correlates: 
Expression ~ Age + Gender + Post-mortem duration + Disease 
Within DESEQ2, p-values for differential expression from Wald tests were corrected 
for multiple testing using the Benjamini-Hochberg false discovery rate approach, with 
significant results reported at α=0.05. Gene ontology (GO) enrichment was performed 
using gProfileR (29). 
Transcriptomic changes were evaluated at the protein level using western blot analysis 
(Supplementary Protocol 1). 
 
Microscopy 
To quantify glial sub-populations and neuropathological lesions in the pulvinar in a 
separate cohort of cases and α-synuclein pathology in the amygdala of the cases used 
for the transcriptomic study, images were taken on a Zeiss AxioVision Z.1 microscope 
using a DsFi1 camera (Nikon, Japan). As detailed previously (21, 30), Stereologer 
software was used to delineate a region of interest with a 2.5x objective, prior to 
placement of disector frames in a uniform, random arrangement. This method 
prevented the introduction of bias by giving every area of the region of interest an 
equal probability of being sampled for analysis. Disector frame sizes were determined 
 
 
based on the size of the measured particles and their distribution across the region of 
interest. In all cases, amyloid-β (4G8 anti-amyloid-β, Covance, NJ, USA, 1:15000) was 
analyzed using 10x objective and α-synuclein (5G4 anti-α-synuclein, Analytik Jena, 
Germany, 1:4500) and tau (AT8 anti-tau, Autogen, MA, USA, 1:4000); the microglial 
markers HLA-DP/DQ/DR (CR3/43, Dako, Denmark, 1:1000), CD74 (LN-2, Santa 
Cruz, USA, 1:500) and Iba1 (Wako, Japan, 1:1000); and the astrocytic markers GFAP 
(Z0334, Dako, Denmark, 1:10000) and ALDH1L1 (N103/39, Millipore, MA, USA, 
1:7500) were measured using 20x objective.  
We determined the percentage area occupied by individual antibodies by analyzing 
images by determining  red-green-blue (RGB) thresholds using ImagePro Plus v.4.1 
image analysis system (Media Cybernetics, Bethesda, MA, USA). Size restriction was 
used with the 4G8 antibody to ensure intracellular amyloid-β was not included in the 
analysis. In addition to quantitative analysis, we qualitatively assessed Iba1 
morphology as described previously (31). We also qualitatively determined the 
presence of Alzheimer Type II astrocytes, the histopathological hallmark of 
manganism and hepatic encephalopathy (32), as their presence was noted in a 
substantial number of cases.  
These findings were correlated with densitometric analyses of neuropathological 
lesion burden to evaluate whether neuroglial marker expression was related to 
pathological protein deposition. A sub-set of cases used for histological analysis (8/14 
control; 8/14 DLB) had been assessed as part of a previous stereological study of the 
pulvinar (21). Therefore, we additionally included stereological determination of total 
neuronal number within these analyses. 
 
  
 
 
RESULTS 
Demographic data 
Demographic data for the RNA-seq and protein expression analysis cohort is shown 
in Supplementary Table 1. There was no significant difference between groups in age 
at death (t=0.18, df=22, p=0.862), post-mortem interval (t=0.17, df=22, p=0.863), and, 
where available, tissue pH (t=0.60, df=15, p=0.555). There was no significant 
difference in the proportion of males relative to females between DLB and control 
(χ²=2.10, df=1, p=0.148). However, the groups were slightly unbalanced with 9/11 DLB 
male and 7/13 controls male. Braak NFT stage was significantly higher in DLB 
compared to control (t=3.85, df=19, p=0.001).  
Demographic data for the histological analysis cohort is shown in Supplementary 
Table 2. There was no significant difference between groups in age at death (t=0.0.23, 
df=26, p=0.982) or post-mortem interval (t=1.23, df=26, p=0.217). There was no 
significant difference in the proportion of males relative to females between DLB and 
control (χ²=0.57, df=1, p=0.706). Braak NFT was significantly higher in DLB cases 
compared to controls (t=3.88, df=26, p=0.001). 
 
Nomination of differential pulvinar gene expression between DLB and controls by RNA 
sequencing 
Our RNA-seq analysis revealed a partial separation between DLB cases and controls 
in overall gene expression (Fig. 1). Quality control data is included in supplementary 
QC file. From this analysis, we nominated 321 transcripts significantly different 
between controls and DLB cases after correction for multiple testing. Subsequently, 
GO enrichment analysis demonstrated several pathways were enriched in DLB cases 
compared to control (Table 1). We focused on genes related to synapses 
(GO:0045202, p=1.75E-25) and positive regulation of immune system process 
(GO:0002684, p=7.75E-22). 
 
Validation of synaptic and immune proteins by western blot analysis 
 
 
Analysis of protein expression using western blot analysis of general pre-synaptic 
markers demonstrated significantly lower expression of synaptophysin (U=30, 
p=0.015), NSF (U=25.5, p=0.006) and dynamin (U=37.5, p=0.047) in DLB compared 
to control (Figure 2). This was consistent with RNA-seq data, which demonstrated 
significantly lower expression of SYP (p=0.01), NSF (p=0.01) and DNM1 (p=0.03). 
However, no significant differences were found in STX1A, SNAP25, SV2B or GAP43, 
despite significantly lower expression at the mRNA level. 
Analysis of protein expression using western blot analysis of general post-synaptic 
markers identified significantly lower expression of the dendritic marker MAP2 (U=35, 
p=0.034) in DLB compared to control (Figure 2), consistent with lower MAP2 mRNA 
(p=0.04). The excitatory synaptic markers PSD-93 (U=25.5, p=0.011) and PSD-95 
(U=27, p=0.009) were also lower in DLB compared to control (Figure 2), consistent 
with reductions in DLG3 (p<0.01) and DLG4 (p<0.01) mRNA.  
The inhibitory synaptic marker GABARAP (U=37, p=0.046) was significantly reduced 
in DLB compared to control (Figure 2), consistent with a reduction in GABARAP mRNA 
(p=0.04). However, protein levels of the inhibitory post-synaptic marker gephyrin were 
not significantly lower in DLB compared to control, despite being lower at the mRNA 
level. The GABA-ergic neuron marker GAD67 was lower in DLB compared to control 
on western blot (U=32, p=0.022), and also at the mRNA level (p=0.02; Figure 2).    
Analyses of CHI3L1, a positive regulator of immune system process and pro-
inflammatory marker (33), demonstrated significantly higher protein levels (U=35, 
p=0.034; Figure 3). The astrocytic marker GFAP was also higher in DLB relative to 
control (U=37, p=0.046; Figure 3). HSPA1B was significantly increased in DLB 
compared to control (U=22, p=0.003). However, SERPINH1/HSP47 and HSPA1A 
were not significantly different in DLB compared to control cases (Figure 3), despite 
showing differences for the same marker in RNA-seq.  
 
Microscopy 
As RNA-seq demonstrated an increase in transcripts related to positive regulation of 
immune system process, we histologically assessed markers of microglia and 
astrocytes, the resident immune cells of the brain, in a separate cohort of DLB and 
 
 
control cases. We assessed the expression of the cytotoxic M1 microglial markers 
CD74 and HLA-DP/DQ/DR, the general microglial marker Iba1 and the astrocytic 
markers ALDH1L1 and GFAP in the pulvinar of DLB cases compared to control. We 
also assessed α-synuclein, amyloid-β and tau expression to evaluate whether immune 
cell expression was related to the presence of neurodegenerative pathologies.  
The observed Lewy body pathology was greater than that previously reported in 
another study of the pulvinar in DLB, which described an absence of Lewy bodies but 
sparse neuritic pathology (22). This discrepancy may be the result of our use of the 
5G4 antibody, which is reported to show more widespread α-synuclein pathology (34). 
Nevertheless,  Lewy bodies were not frequently encountered within the pulvinar of 
most cases, with Lewy body burden typically corresponding to absent or mild 
deposition under previously described semi-quantitative assessment methods (4). 
However, we noted an abundance of α-synuclein immunoreactive dots and occasional 
fine threads, as noted previously with the 5G4 antibody (35). 
α-synuclein (U=0, p<0.001), amyloid-β (U=39, p=0.006) and tau (U=37, p=0.004) were 
higher in the pulvinar of DLB cases compared to those of controls (Fig. 4). Although 
AIF1 mRNA was significantly elevated in the DLB pulvinar on RNA-seq (p=0.003), its 
protein product Iba1 was not increased on histological analysis (Supplementary Figure 
1). Similarly, CD74 mRNA was significantly higher in DLB (p=0.02) but was not 
different on histological analysis (Supplementary Figure 1). Although some specific 
sub-types of HLA-D were significantly increased at the mRNA level, there was no 
significant difference in expression of HLA-DP/DQ/DR on histological analysis 
(Supplementary Figure 1). The astrocytic marker ALDH1L1 was not significantly 
different on RNA-seq or histological analysis between DLB and controls. However, 
GFAP was significantly higher in DLB cases compared to controls at the mRNA level 
(p=0.001) and on histological analysis (U=18, p=0.001; Supplementary Figure 1). 
A range of different microglial morphologies were observed across cases and within 
experimental groups (Supplementary Figure 2). Possibly as a result of the 
considerable heterogeneity in morphologies within groups, no morphology was 
significantly associated with either experimental group (χ²=4.5, p=0.214; 
Supplementary Figure 3). Furthermore, individual microglial morphologies were not 
associated with any histopathological or glial marker. Alzheimer type-II astrocytes 
 
 
were not more frequently encountered in DLB cases compared to control (χ²=2.8, 
p=0.104; Supplementary Figure 3). 
 
Relationship between synaptic loss and neuropathological changes 
To evaluate whether synaptic loss corresponded to neuropathological changes in a 
region projecting to the pulvinar, we quantified the burden of α-synuclein pathology in 
the amygdala, a region connected to the pulvinar through a pathway reported to be 
dysfunctional in DLB (20). Of the nine synaptic markers significantly reduced in DLB 
compared to control only PSD-93 was significantly negatively correlated with α-
synuclein burden in the amygdala (rs=-0.729, p=0.017). 
 
Relationship between astrocytic increases and neuropathological, stereological and 
synaptic changes 
After identifying an increase in GFAP in DLB compared to control, we next evaluated 
the relation of this marker to the presence of neuropathological lesions, neuronal loss 
and synaptic changes. To prevent spurious correlations being identified due to group 
differences, DLB cases were analyzed separately from controls. The histological 
expression of GFAP was not significantly related to amyloid-β, tau or α-synuclein in 
DLB cases. Within the sub-set of cases assessed using stereological determination of 
neuronal number (8/14) as reported previously (21), GFAP was not related to neuronal 
number. 
Employing two distinct cohorts of cases for transcriptomic and histological analyses 
limited our ability to compare histologically assessed glial markers and synaptic 
markers assessed with western blot. Therefore, we also assessed GFAP using 
western blot analysis to investigate whether GFAP expression was related to synaptic 
changes in DLB. GFAP (50 kDa) was significantly negatively correlated with 
synaptophysin (rs=-0.621, p=0.041), dynamin (rs=-0.655, p=0.029), GABARAP (rs=-
0.673, p=0.023), and GAP43 (rs=-0.627, p=0.039) in DLB cases. 
 
 
 
Clinico-pathological correlations 
A sub-set of DLB cases (9/14) used for histological analysis had been subject to 
neuropsychological evaluation intra vitam. As detailed previously (30), these 
individuals had been assessed using the hallucinations subscale of the 
Neuropsychiatric Inventory (NPI) within two years prior to death (36). Comparison of 
NPI hallucinations score with neuropathological markers and GFAP demonstrated a 
significant positive correlation only between tau burden and NPI hallucination subscale 
score (rs=0.701, p=0.035). There were no significant correlations between NPI 
hallucinations subscale and any other variable.    
 
 
DISCUSSION 
Using a transcriptomic approach, the present study has demonstrated synaptic 
changes and astrogliosis in the pulvinar in DLB. Notably, these findings occurred in a 
region that typically manifests relatively mild α-synuclein deposition yet is postulated 
to play a central role in the cognitive profile of DLB. The reported changes differ 
markedly from a previous study that employed RNA-seq in the cingulate gyrus, a 
region with more severe α-synuclein pathology (2), and which reported genes involved 
in neurogenesis and myelination enriched in DLB compared to control (37). 
The reported synaptic changes indicate lower expression levels of pre-synaptic 
proteins such as synaptophysin and NSF which support efficient turnover of vesicles 
following exocytotic events (38). In contrast, we found preservation of proteins 
necessary for vesicular exocytosis, such as SNAP25 (39), STX1A (40), and SV2B 
(41). Despite the interaction of α-synuclein with synaptic proteins, previous studies 
have not consistently demonstrated significantly lower levels of pre-synaptic markers 
in DLB (42).  
The role of glia in DLB has been a matter of controversy and debate, with conflicting 
reports in the literature. Microglial activation is induced by aggregated α-synuclein in 
vitro (43), though post-mortem studies have reported inconsistent findings (31, 44-46). 
Despite RNA-seq demonstrating enrichment of transcripts related to positive 
regulation of immune system processes, we found no evidence of such changes at 
the protein level. Therefore, our data favor the view that microglia-mediated 
neuroinflammatory processes are not an important factor in the reported synaptic 
changes. However, it is impossible to exclude the possibility that an acute 
inflammatory response occurred earlier in the disease process but was undetectable 
in terminal stages.  
As GFAP immunoreactivity did not correlate with any pathological lesion or neuronal 
loss, astrogliosis does not seem to be a response to neurodegenerative lesions within 
the pulvinar. It is noteworthy that astrogliosis was not accompanied by microgliosis 
and thus does not appear to signify a neuroinflammatory state. Considering the 
negative relationship between reactive astrogliosis and several synaptic markers, we 
speculate that reactive astrogliosis may be a response to synaptic dysfunction, with 
the aim of supporting synaptic transmission. Further studies are warranted to evaluate 
 
 
the role of astrocytes in Lewy body diseases, and whether they have a protective or 
degenerative function. Elucidating the role of astrocytic sub-populations in 
neurodegenerative disorders may identify novel therapeutic targets to augment 
protective functions or attenuate degenerative processes. 
The role of the pulvinar as a ‘hub’ modulating cortico-cortical activity may suggest that 
the present findings are the neuropathological substrate of desynchronous network 
coherence in DLB. The pulvinar exerts a powerful influence on cortical activity based 
on attentional demands (47) meaning its dysfunction likely impacts attention-mediated 
cortical functions. Attention is deficient in DLB (48, 49), and has been implicated in 
visual hallucinations and fluctuating cognition (11, 48). The search for the 
neuropathological substrates of symptoms such as visual hallucinations and cognitive 
fluctuations is impeded by the inherent difficulty in attributing a transient feature to a 
permanent neuropathological change. However, dysfunction of structures regulating 
cortical functioning on the basis of attention may be more likely to contribute to 
transient features of neurodegenerative diseases. 
The reported findings are within a region with relatively low levels of Lewy body 
pathology and differ from those reported in a more severely affected region, the 
cingulate gyrus (37). These findings indicate important molecular changes, in addition 
to previously reported neuronal loss (21), independent of the severity of local 
neuropathological changes. Although we noted a relationship between tau pathology 
in the pulvinar and the frequency and severity of visual hallucinations intra vitam, the 
overall levels of tau were very low in the pulvinar in DLB. Furthermore, these findings 
are hard to reconcile with our previous report of higher tau burdens in the pulvinar of 
Alzheimer’s disease cases without visual hallucinations compared to DLB (50). The 
tau burden in the pulvinar may be a proxy measure of global tau burden, which has 
been previously reported to influence the clinical phenotype of DLB (51). 
As the pulvinar is highly interconnected with numerous cortical and sub-cortical areas, 
one may speculate that the reported findings are a downstream result of 
neuropathological changes to regions connected to the pulvinar. We identified a strong 
negative correlation between PSD-93 and α-synuclein burden in the amygdala, a 
region connected to the pulvinar. Whilst a similar relationship was not found with other 
synaptic markers, the pulvinar as a ‘hub’ region has widespread connectivity across 
 
 
the cortex (13) and a systematic evaluation of the many regions connected to it was 
beyond the scope of this study. Molecular changes in ‘preserved’ regions as a result 
of neuropathological changes elsewhere may be particularly relevant to the 
aetiopathology of Lewy body diseases, considering the relatively selective topography 
of α-synuclein deposition (52). Therefore, relative preservation of brain structures may 
have important implications for the clinical phenotype of DLB and studies focusing only 
on regions with severe α-synuclein deposition may miss pathological alterations 
relevant to the clinical phenotype of Lewy body disease. 
In summary, we have identified changes on the molecular level in the pulvinar, a region 
with relatively low levels of Lewy body pathology, but that is thought to have an 
important influence upon the cognitive phenotype of DLB (13). One may speculate 
that the reported synaptic and astroglial changes are a downstream effect of 
neurodegenerative changes elsewhere and suggest that the absence of a significant 
local pathological burden should not be assumed to indicate functional preservation.   
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